Navitas Life Sciences

Rapid Development of immunogenicity testing to detect Anti-Glargine antibodies with Successful Deployment to Phase III Trial

Our client, a global pharma, with footprints across Asia Pacific, Africa, Eurasia & Latin America, required a strategic partner with end-to-end capabilities in developing Ligand Binding Assay (LBA) and ADA assay to detect Anti-Glargine antibodies.

  • Proven expertise and knowledge in developing and validating assays within set deadlines and high-quality benchmarks.
  • Design assays that are precise, sensitive, and robust assays, adhering to global regulatory norms for identifying Anti-Glargine antibodies.
  • Provide economical and efficient assistance that aligns with both time and financial limitations.
  • Timely development and validation of the assay, aligning with stringent schedules. The tight timeline was crucial due to synchronized clinical development and imminent sample arrival (4-5 months).

Please complete the form to download the Case Study and learn how Navitas Life Sciences leveraged its LBA capabilities for stellar immunogenicity testing, developing a new immunogenicity assay for Anti Glargine antibodies, with study completion in just 4 weeks.

Please complete the form to download the case study
First Name
Last Name
Business Email
Job Title
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy

© 2023 Navitas Life Sciences | Privacy Policy